Limits...
Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.

Shiratsu K, Higuchi K, Nakayama J - Cancer Sci. (2013)

Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.

Show MeSH

Related in: MedlinePlus

Mucin expression in gastric cancer. (a) MUC5AC-, MUC6-, and MUC2-positive differentiated carcinoma. (b) MUC6-positive differentiated carcinoma. Tumor cells are negative for other markers. (c) MUC2- and CD10-positive differentiated carcinoma. (d) MUC5AC- and MUC6-positive undifferentiated carcinoma. Tumor cells are negative for MUC2 and CD10. Scale bar = 500 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317868&req=5

fig01: Mucin expression in gastric cancer. (a) MUC5AC-, MUC6-, and MUC2-positive differentiated carcinoma. (b) MUC6-positive differentiated carcinoma. Tumor cells are negative for other markers. (c) MUC2- and CD10-positive differentiated carcinoma. (d) MUC5AC- and MUC6-positive undifferentiated carcinoma. Tumor cells are negative for MUC2 and CD10. Scale bar = 500 μm.

Mentions: Representative expression of each marker in tumor cells is shown in Figure1. Among 101 differentiated-type adenocarcinomas, 38.6%, 53.4%, 21.7%, and 22.7% were positive for MUC5AC, MUC6, MUC2, and CD10, respectively, Among 113 undifferentiated-type adenocarcinomas, 46%, 42.4%, 23.8%, and 20.3% were positive for MUC5AC, MUC6, MUC2, and CD10, respectively.


Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.

Shiratsu K, Higuchi K, Nakayama J - Cancer Sci. (2013)

Mucin expression in gastric cancer. (a) MUC5AC-, MUC6-, and MUC2-positive differentiated carcinoma. (b) MUC6-positive differentiated carcinoma. Tumor cells are negative for other markers. (c) MUC2- and CD10-positive differentiated carcinoma. (d) MUC5AC- and MUC6-positive undifferentiated carcinoma. Tumor cells are negative for MUC2 and CD10. Scale bar = 500 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317868&req=5

fig01: Mucin expression in gastric cancer. (a) MUC5AC-, MUC6-, and MUC2-positive differentiated carcinoma. (b) MUC6-positive differentiated carcinoma. Tumor cells are negative for other markers. (c) MUC2- and CD10-positive differentiated carcinoma. (d) MUC5AC- and MUC6-positive undifferentiated carcinoma. Tumor cells are negative for MUC2 and CD10. Scale bar = 500 μm.
Mentions: Representative expression of each marker in tumor cells is shown in Figure1. Among 101 differentiated-type adenocarcinomas, 38.6%, 53.4%, 21.7%, and 22.7% were positive for MUC5AC, MUC6, MUC2, and CD10, respectively, Among 113 undifferentiated-type adenocarcinomas, 46%, 42.4%, 23.8%, and 20.3% were positive for MUC5AC, MUC6, MUC2, and CD10, respectively.

Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.

Show MeSH
Related in: MedlinePlus